Patents by Inventor Xiao Min Schebye
Xiao Min Schebye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230382992Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: February 27, 2023Publication date: November 30, 2023Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Publication number: 20230174647Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.Type: ApplicationFiled: June 21, 2022Publication date: June 8, 2023Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
-
Patent number: 11591392Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: GrantFiled: November 27, 2019Date of Patent: February 28, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong
-
Patent number: 11401328Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.Type: GrantFiled: July 9, 2019Date of Patent: August 2, 2022Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
-
Publication number: 20220089720Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.Type: ApplicationFiled: January 11, 2019Publication date: March 24, 2022Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Publication number: 20210363242Abstract: This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.Type: ApplicationFiled: January 15, 2019Publication date: November 25, 2021Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle Renne KUHNE, Hong-An TRUONG, Poliana PATAH, Jeffrey R. JACKSON, Ronald A. FLEMING
-
Publication number: 20200190186Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: November 27, 2019Publication date: June 18, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Publication number: 20200079848Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.Type: ApplicationFiled: July 9, 2019Publication date: March 12, 2020Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
-
Patent number: 10533052Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: GrantFiled: June 25, 2018Date of Patent: January 14, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong
-
Patent number: 10400040Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: GrantFiled: June 16, 2017Date of Patent: September 3, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Publication number: 20190248893Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: July 13, 2017Publication date: August 15, 2019Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Y. HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Publication number: 20180298097Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: June 25, 2018Publication date: October 18, 2018Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F,. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Troung
-
Patent number: 10077306Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: GrantFiled: July 13, 2017Date of Patent: September 18, 2018Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Troung
-
Patent number: 10023634Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: GrantFiled: July 13, 2017Date of Patent: July 17, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Troung
-
Publication number: 20180016336Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: July 13, 2017Publication date: January 18, 2018Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TROUNG
-
Publication number: 20170355772Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: ApplicationFiled: June 16, 2017Publication date: December 14, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Patent number: 9701751Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: GrantFiled: April 24, 2014Date of Patent: July 11, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Publication number: 20140348841Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: ApplicationFiled: April 24, 2014Publication date: November 27, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Patent number: 8709424Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: GrantFiled: August 31, 2010Date of Patent: April 29, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Publication number: 20120189639Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: ApplicationFiled: August 31, 2010Publication date: July 26, 2012Applicant: Schering CorporationInventors: Xiao Min Schebye, Grigory P. Ermakov, Douglas J. Hodges, Leonard G. Presta
